EGFR and breast cancer: Recent studies in mouse mammary tumors have shown that activation of the Ron related receptor, c-Met, is responsible for increased tumor blood flow as well as serving as a mechanism of resistance to a number of targeted therapies including those directed against EGFR, VEGF and B-Raf [34].